CAP and ASCO have well-defined guidelines and stratification of BC into HER2-neg, equivocal or HER2-pos cases and our concordance rate of more than 80% in the validation cohort comparing routine pathology and DEPArrayTM-HER2-FISH analysis strengthens this definition. This evidence concerns the gene ERBB2 and breast cancer.